Drug intelligence / Profile preview

3D6-k

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intraperitoneal

Overview

3D6-k is a modified murine anti-amyloid monoclonal antibody, specifically a CDC-mutant (K322A) version of the 3D6 antibody. It is designed to block C1q binding, thereby reducing complement activation associated with amyloid-related imaging abnormalities (ARIA), an adverse vascular side effect observed in anti-amyloid immunotherapy for Alzheimer's disease. While maintaining similar fibrillar amyloid clearance capabilities as its parent antibody 3D6, 3D6-k aims to mitigate ARIA by reducing C1q/antibody colocalization in plaques and subsequent complement pathway activation.

Other names: CDC-mutant (K322A) 3D6

Targets

C1Q (Complement C1q)Amyloid-beta aggregate (N-terminal epitope)

Beyond the preview

Go deeper on 3D6-k.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3D6-k.

Explore the full profile